Recently, DFPP combined with IFN and RBV has been used in CHC patients with high viral load and living donor liver transplant recipients with hepatitis C. All these clinical studies demonstrated that DFPP appeared to be effective in reducing viremia and preventing HCV recurrence in patients. This evidence concerns the gene IFNA1 and cryohydrocytosis.